Jove
Visualize
联系我们

相关概念视频

Randomized Experiments01:13

Randomized Experiments

9.1K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
9.1K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

621
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
621
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

488
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
488
Cancer Survival Analysis01:21

Cancer Survival Analysis

784
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
784
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

634
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
634
Clinical Trials01:16

Clinical Trials

10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Model-Informed Dosing Strategies for Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma.

Clinical pharmacology and therapeutics·2026
Same author

When Selectivity Increases Uncertainty: Context-Dependent Pharmacology in Antibody Drug Development.

Clinical and translational science·2026
Same author

Quantitative Lesion-Level Modeling Reveals Organ-Dependent Therapeutic Response.

Clinical pharmacology and therapeutics·2026
Same author

A preliminary proof-of-concept trial on the effects of ketamine on fatigue: a randomized crossover trial.

Pharmacological reports : PR·2026
Same author

Cleaning and pre-processing of actigraphy data for physical activity and sleep research: a scoping review.

Physiological measurement·2026
Same author

Antibody Transfer From Mother to Fetus/Infant: An Opportunity for Model-Informed Precision Medicine.

Journal of clinical pharmacology·2025
Same journal

Correction to "Physicians' Perceptions of Prescribing in Pregnancy and Package Inserts: A Survey of General and Hub Hospitals in Japan".

Clinical and translational science·2026
Same journal

Development of Core Competencies in Clinical Data Science Graduate Education: A Follow-On Tutorial to From Clinical Data Management to Clinical Data Science: Time for a New Educational Model.

Clinical and translational science·2026
Same journal

Population Pharmacokinetic, Exposure-Response Efficacy and Safety Analyses of Favezelimab in Patients With Solid Tumors.

Clinical and translational science·2026
Same journal

Development of a Biphasic Modified-Release Ibuprofen Tablet Formulation: Single-Dose and Multiple-Dose Pharmacokinetics and Food-Effect Studies.

Clinical and translational science·2026
Same journal

Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study.

Clinical and translational science·2026
Same journal

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod.

Clinical and translational science·2026
查看所有相关文章
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Feb 17, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.9K

预测模型引导的随机化提高了早期试验的效率:来自调查和模拟的证据.

Sihong Zhang1, Justin Zhao1, Yanguang Cao1,2

  • 1Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Clinical and translational science
|February 16, 2026
PubMed
概括
此摘要是机器生成的。

改善早期瘤学试验需要更好的随机化. 使用像ROPRO这样的预后模型,而不仅仅是ECOG状态,增强了统计能力,并减少了检测治疗效应的样本大小需求.

关键词:
临床试验临床试验临床试验临床试验临床试验预测模型的预测模型.这个项目是Optimus Optimus.随机化是一种随机化.

更多相关视频

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.6K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

8.2K

相关实验视频

Last Updated: Feb 17, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.9K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.6K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

8.2K

科学领域:

  • 在瘤学瘤学.
  • 临床试验 临床试验
  • 生物统计学 生物统计学

背景情况:

  • 早期瘤学试验在检测治疗效果方面面临挑战,原因是样本规模小,患者异质.
  • 标准随机化往往不充分利用关键预后因素,可能减少统计能力并引入偏差.
  • 已建立的预后变量,如ECOG性能状态,在当前的试验设计中经常被不足利用.

研究的目的:

  • 评估基于预后模型的随机化策略,使用现实世界预测得分 (ROPRO).
  • 为了比较基于ROPRO的随机化与基于ECOG的随机化的统计能力和样本大小要求.
  • 支持在早期瘤学试验中使用预后模型信息随机化,与FDA的最佳项目目标保持一致.

主要方法:

  • 在clinicaltrials.gov上调查了113项随机瘤学试验,以评估预后因素的利用率.
  • 开发了现实世界预测得分 (ROPRO),将27个基线变量集成到单个风险得分中.
  • 采用半合成模拟来比较基于ROPRO的随机化与ECOG随机化在各种生存模型和治疗效果大小.

主要成果:

  • 与ECOG随机化相比,基于ROPRO的随机化始终提高了统计能力.
  • 罗普罗战略减少了检测治疗效应所需的样本大小.
  • 功率优势在+1至+11个百分点之间,在适度的样本大小下显著增长.

结论:

  • 以预测模型为基础的随机化策略,如使用ROPRO,在早期瘤学试验中增强了统计能力.
  • 这种方法可以通过减少样本大小要求,导致更有效的试验设计.
  • 在注册试验之前,实施先进的随机化方法对于优化剂量和治疗方案选择至关重要.